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METHODOLOGY
A panel of recombinant proteins 
from human‑infective Plasmodium species 
for serological surveillance
Nicole Müller-Sienerth1†, Jarrod Shilts1†, Khamisah Abdul Kadir2, Victor Yman3, Manijeh Vafa Homann3, 
Muhammad Asghar3, Billy Ngasala4,5, Balbir Singh2, Anna Färnert3,6 and Gavin J. Wright1* 
Abstract 
Background: Malaria remains a global health problem and accurate surveillance of Plasmodium parasites that are 
responsible for this disease is required to guide the most effective distribution of control measures. Serological sur-
veillance will be particularly important in areas of low or periodic transmission because patient antibody responses 
can provide a measure of historical exposure. While methods for detecting host antibody responses to Plasmodium 
falciparum and Plasmodium vivax are well established, development of serological assays for Plasmodium knowlesi, 
Plasmodium ovale and Plasmodium malariae have been inhibited by a lack of immunodiagnostic candidates due to 
the limited availability of genomic information.
Methods: Using the recently completed genome sequences from P. malariae, P. ovale and P. knowlesi, a set of 33 
candidate cell surface and secreted blood-stage antigens was selected and expressed in a recombinant form using 
a mammalian expression system. These proteins were added to an existing panel of antigens from P. falciparum and 
P. vivax and the immunoreactivity of IgG, IgM and IgA immunoglobulins from individuals diagnosed with infections 
to each of the five different Plasmodium species was evaluated by ELISA. Logistic regression modelling was used to 
quantify the ability of the responses to determine prior exposure to the different Plasmodium species.
Results: Using sera from European travellers with diagnosed Plasmodium infections, antigens showing species-
specific immunoreactivity were identified to select a panel of 22 proteins from five Plasmodium species for serologi-
cal profiling. The immunoreactivity to the antigens in the panel of sera taken from travellers and individuals living in 
malaria-endemic regions with diagnosed infections showed moderate power to predict infections by each species, 
including P. ovale, P. malariae and P. knowlesi. Using a larger set of patient samples and logistic regression modelling it 
was shown that exposure to P. knowlesi could be accurately detected (AUC = 91%) using an antigen panel consisting 
of the P. knowlesi orthologues of MSP10, P12 and P38.
Conclusions: Using the recent availability of genome sequences to all human-infective Plasmodium spp. parasites 
and a method of expressing Plasmodium proteins in a secreted functional form, an antigen panel has been compiled 
that will be useful to determine exposure to these parasites.
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Background
Malaria is an infectious disease that remains a global 
health problem causing an estimated 219 million clinical 
cases resulting in 435,000 deaths in 2017 [1]. he disease 
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is caused by parasites of the genus Plasmodium and sev-
eral species are known to regularly infect humans. he 
vast majority of deaths occur in sub-Saharan Africa and 
are caused by Plasmodium falciparum, whereas outside 
of Africa, Plasmodium vivax is responsible for over half 
of all malaria infections leading to signiicant morbidity 
and mortality [2]. Much less is known about the other 
human-infective Plasmodium species, Plasmodium 
malariae, Plasmodium ovale and Plasmodium knowlesi 
both in terms of their global distribution and clinical 
impact. Plasmodium knowlesi, a parasite typically found 
in macaques, is a signiicant cause of human malaria in 
Southeast Asia, causing a spectrum of disease ranging 
from mild to fatal infections [3]. Malaysia has the high-
est incidence of P. knowlesi malaria with over 6700 cases 
reported in the last 2 years compared to only 85 cases of 
indigenous human malaria (unpublished data from the 
Ministry of Health, Malaysia).
Diagnosis of Plasmodium infections and epidemio-
logical surveillance is important for guiding the dis-
tribution of resources into intervention measures and 
establishing their clinical impact over time [4]. Methods 
to measure the prevalence of Plasmodium infections 
include microscopy, rapid diagnostic tests (RDTs) and 
PCR-based approaches, each difering in their sensitiv-
ity, infrastructure requirements, and ability to diagnose 
the diferent species. Serological assays can provide a his-
torical record of infection and because of the speciicity 
of antibody-antigen binding, could also potentially dis-
criminate between diferent Plasmodium spp. infections. 
Host antibodies appear rapidly after initial infection and 
can persist for months and even years after the parasites 
have been cleared [5, 6]. Serological screening has been 
applied in epidemiological settings to detect parasite 
exposure, evaluate transmission trends of malaria [7–10], 
and identify antibody-based correlates of protection [11, 
12]. It is also used in blood donation centres, where, due 
to the increase in international travel and migration, the 
need for serological diagnosis is becoming more impor-
tant to reduce the risk of transfusion-transmitted infec-
tions. Currently, many centres assess these risks using 
patient questionnaires which is generally unsatisfactory; 
moreover, the limitations and costs of the currently avail-
able serological tests often make implementing these 
assays economically unattractive [13].
Many antibodies recognise epitopes that are only 
formed in the context of an antigen in its native con-
formation [14]. To detect these antibodies, it is vitally 
important that the proteins used are correctly folded 
so that they faithfully form these epitopes. Expressing 
Plasmodium proteins in a soluble recombinant form has 
proved challenging, perhaps because of the high A:T 
content of the genome and lack of recognisable protein 
domains in many Plasmodium proteins [15]. his prob-
lem is especially acute for parasite proteins that are 
secreted or embedded in membranes because these 
proteins additionally contain structurally critical post-
translational modiications, such as disulide bonds that 
are not typically added by many commonly used expres-
sion systems. Recently, a method of expressing large 
panels of recombinant Plasmodium proteins was devel-
oped that retained many of their biochemical functions 
[16]. Central to this approach was the use of a mamma-
lian expression system which increases the chances that 
appropriate post-translational modiications are correctly 
added to ensure proteins adopt their native fold. For anti-
gens expressed using this method a large fraction—and 
in some cases all—the immunoreactivity to antigens was 
heat-labile, demonstrating that antibodies that recognise 
conformational epitopes represent a major component of 
the humoral response [16]. Previously, this approach was 
used to create libraries of soluble recombinant merozo-
ite cell surface and secreted proteins that encompass the 
entire ectodomain from both P. falciparum [16, 17] and 
P. vivax [18]. Using sera from patients living in endemic 
regions, several of these proteins were found to be highly 
immunoreactive and might therefore be useful target 
antigens in serological assays [8, 12]. Expanding the anti-
gen panel to include the other parasite species infecting 
humans would be especially valuable if they could be 
used to determine exposure to the diferent species of 
Plasmodium. Here, the recent availability of high-quality 
genome sequences from the three other human-infective 
Plasmodium parasites: P. knowlesi, P. ovale and P. malar-
iae were used to extend the available panel of proteins 
and were tested for reactivity to sera from individuals 
infected with diferent Plasmodium parasites.
Methods
Study populations
Collection of sera from Malawian adults that were  pre-
viously used to determine its efectiveness as an adjunct 
therapy to treat cerebral malaria was approved by the 
National Health Sciences Research Committee of Malawi 
[19]. Plasma from adult travellers, microscopy-diagnosed 
with malaria and species further conirmed by multiplex 
PCR for all species except P. knowlesi [20] after return-
ing from visits to malaria-endemic regions were obtained 
from the Karolinska University Hospital, Stockholm, 
Sweden (n = 81). Of these, 53 were from travellers of 
European origin and 28 from travellers born in malaria-
endemic regions as follows: Angola (3 individuals), 
Burundi (1), Cameroon (1), Democratic Republic of the 
Congo (1), Eritrea (4), Ethiopia (1), he Gambia (1), India 
(3), Ivory Coast (2), Kenya (5), Pakistan (1), hailand (1), 
and Uganda (4). Plasma from an endemic region with 
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diagnosed infections were from a longitudinally followed 
population from Nyamisati, in the Ruiji region, Tanzania 
(n = 21) in 1994 when transmission was high [21]. Swed-
ish residents with no history of visiting malaria-endemic 
countries were included as controls (n = 28). Ethical 
approval was granted by the Ethical Review Board of the 
National Institute for Medical Research in Tanzania, and 
the Regional Ethical Review Board in Stockholm, Sweden 
(Dnr. 00-084, 2012/1151-32, 2006/893-31/4, 2018/2354-
32). Serum samples from adult malaria patients with 
PCR-conirmed P. knowlesi mono-infection were col-
lected at Kapit Hospital in Malaysian Borneo (n = 50) 
and from uninfected adult controls from Kapit Divi-
sion (n = 66) after informed consent had been obtained. 
Approval to conduct this study was obtained from the 
Medical Research and Ethics Committee of the Minis-
try of Health, Malaysia and the Medical Ethics Commit-
tee, Faculty of Medicine and Health Sciences, Universiti 
Malaysia Sarawak.
Recombinant protein construct design, expression 
and manipulation
he orthologues of immunoreactive blood-stage antigens 
from P. knowlesi, P. malariae and P. ovale were identi-
ied from their respective genome sequences [22–24]. 
For P. ovale, proteins from Plasmodium ovale curtisi 
were selected since the manual gene annotation of this 
genome resulted in complete open reading frames com-
pared to the draft genome available for Plasmodium 
ovale wallikeri [24]. Sequences corresponding to the 
entire ectodomains were identiied using software tools 
to predict the location of the signal peptides, GPI-anchor 
and transmembrane regions [25, 26]. In some cases, for 
example, P. malariae P38, this analysis helped improve 
automated gene prediction by identifying missing signal 
peptides. Based on these predictions, the ectodomain 
regions were determined by removing signal sequences 
and transmembrane domains. All potential N-linked gly-
cosylation sites were systematically mutated by substitut-
ing the serine/threonine in the context of an N-linked 
glycosylation sequon for alanine to prevent inappropri-
ate glycosylation when expressed in mammalian cells as 
described  previously [16]. All sequences were codon-
optimized for expression in human cells, lanked with 
unique 5′ NotI and 3′ AscI restriction enzyme sites to 
allow inframe cloning in a plasmid containing a highly 
eicient mouse variable κ light chain signal peptide [27] 
and a rat Cd4d3+ 4 epitope tag followed by either a pep-
tide sequence allowing enzymatic biotinylation and/or 
6-his tag for puriication [28]. Proteins were expressed 
by transient transfection in suspension-grown HEK293E 
[29] and HEK293-6E cells [30], essentially as described 
previously [31]. In brief, HEK293 cells were seeded the 
day prior to transfection at a density of 2.5 × 105 cells 
 mL−1 (HEK293E) or 1.0 × 106 cells  mL−1 (HEK293-6E). 
Cells are routinely cultured in volumes of 50 mL in Free-
style293 media following the manufacturer’s recommen-
dations; for HEK293E cells, the media is supplemented 
with 1% FCS. To ensure eicient biotinylation, the cell 
culture media used to produce bait proteins with D-bio-
tin to a inal concentration of 100  μM. he following 
day, cells were transfected as described [31] using either 
25 μg (HEK293E) or 50 μg (HEK293-6E) of the bait plas-
mid constructs. To enzymatically monobiotinylate pro-
teins, cells were co-transfected with a plasmid encoding 
a secreted version of the Escherichia coli BirA enzyme 
(Addgene plasmid number 64395), at a 10:1 ratio, 
essentially as described [31]. Cultures were harvested 6 
(HEK293E) or 5 (HEK293-6E) days post-transfection by 
irst pelleting the cells by centrifugation at 3000×g for 
20 min followed by iltration of the supernatant through 
a 0.22 μM ilter. His-tagged proteins were puriied from 
spent tissue culture supernatant with either a 1 mL His-
Trap HP column (GE Healthcare) using an ÄKTAxpress 
or ÄKTApure instrument (GE Healthcare) or a bespoke 
puriication instrument for parallel protein puriication 
[28] in a His MultiTrap HP 96-well plate (GE Healthcare).
Western blotting
To determine protein integrity, 10 µL of transfection 
supernatant was resolved by SDS-PAGE using Novex 
NuPAGE 4–12% Bis Tris precast gels (Life Technologies) 
under reducing conditions, transferred to nitrocellulose 
membrane (Invitrogen), blocked with 2% BSA in phos-
phate-bufered saline (PBS)/0.1% Tween-20 (PBST), and 
probed with 0.02  µg/mL of streptavidin-HRP (Jackson 
Immunoresearch) diluted in PBS-2% BSA. After washing, 
biotinylated proteins were detected by addition of Super-
Signal West Pico Chemiluminescent substrate (PIERCE) 
and developed on photographic ilm (Amersham Hyper-
ilm ECL, GE Healthcare).
Enzyme‑linked immunosorbent assay (ELISA)
ELISAs were performed by capturing biotinylated bait 
proteins into individual wells of streptavidin-coated 
384-well plates  (Greiner Bio-one). Plates were washed 
for 30 min with 50 μL PBS-T (0.2% Tween) and blocked 
with PBS-2% BSA for a minimum of 3 h. 20 μL of a bait 
protein diluted in PBS-2% BSA at a concentration previ-
ously determined as the amount required to saturate the 
biotin binding capacity of the well were added in trip-
licate and incubated for at least 16  h at 4  °C. Antisera 
were centrifuged at 13,000 rpm for a minimum of 1 h at 
4  °C, diluted in PBS-2% BSA and incubated with rota-
tion for at least 16 h at 4 °C before adding to the antigen-
coated plates for 1 h. Serum dilutions used were: native 
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Tanzanians 1:5000, native Malaysians 1:1000, imported 
malaria 1:500–1:1000, European travellers 1:100–1:500, 
and Malawian pooled sera resuspended to 20  mg  mL−1 
and used 1:1000. Plates were washed 3× in PBS-T before 
incubating with 1:10,000 dilution of peroxidase-con-
jugated AiniPure goat anti-human IgA + IgG + IgM 
(H + L) (Jackson ImmunoResearch) in PBS-2%BSA for 
1  h. Plates were washed in PBS-T and the HRP sub-
strate ABTS (KPL) was added and absorption at 405 nm 
determined using an automated plate reader (FluoStar 
Optima, BMG Labtech).
Data analysis
Data are available in Additional ile 1 and all data analy-
sis was performed in R (version 3.5.2). Background sig-
nals from a negative control well were subtracted from 
ELISA absorbance data, and because there was little sig-
nal to most antigens for each patient, the median across 
all antigens was used as a robust measure of background 
immunoreactivity. For cross-reactivity analysis, pairwise 
Spearman correlations between each measured antigen 
were calculated across patient sera. Immunoreactivity 
values that were negative after background subtraction 
were rounded to zero to avoid correlating uninformative 
negative signals. Signiicance tests for each rank correla-
tion were corrected for multiple-testing using the Benja-
mini–Hochberg procedure. Based on the results of the 
cross-reactivity analysis, all antigens with signiicantly 
correlated immunoreactivity across diferent species 
were excluded from further analysis (PfHPzz, PvHPzz, 
PmP41, PmMSP5, PvMSP5). Logistic regression models 
to predict exposure were computed using the generalized 
linear models “glm” function in R. One model was itted 
per species, making a total of ive classiiers. For every 
model, each patient was designated as either: diagnosed 
for that particular species (either by qPCR or micros-
copy); a negative control from a non-endemic region with 
no infection history; or, as ambiguous, if the patient lived 
in an endemic region, but was not diagnosed for that par-
ticular species. Ambiguous cases were omitted in model 
training, since they could not be classiied reliably. Once 
labelled, the data sets were randomly divided approxi-
mately 50:50 into a testing set and training set. Logistic 
regression models were it to the training set, then evalu-
ated on the testing sets. Receiver operating characteristic 
(ROC) curves were calculated using the model predic-
tions on the testing set and their known diagnosed labels. 
Curves were coloured by an arbitrary cost function, sum-
ming the number of false positives and false negatives at 
each threshold to highlight the relative optima [32, 33]. 
he area under the curve (AUC) was calculated using 
the PRROC package [34]. To determine a conidence-
interval for the ROC curve estimates, the model itting 
and evaluation process was repeated for 10 diferent ran-
dom splits of the data into training and testing sets. Aver-
age true positive and false positive rates were calculated 
at each threshold, along with a 95% conidence inter-
val from the 10 stratiications. When calculating model 
scores across all patients for every species the same pro-
cedure was followed except 100 instead of 10 random 
sub-samplings were used to ensure that every patient was 
included on at least one testing set after random splitting.
Results
With the aim of identifying antigens that could be used 
for serological markers of infection for Plasmodium para-
sites that infect humans, 12 proteins from P. falciparum 
and 10 proteins from P. vivax which were previously 
shown to be highly immunoreactive to sera from patients 
living in endemic regions were selected [12, 18] (Table 1). 
From these proteins, 8 that were produced at high lev-
els in the expression system (CyRPA, GAMA, MSP10, 
MSP4, MSP5, P12, P38, P41) were selected to identify the 
orthologous proteins from the genome sequences of P. 
knowlesi [22], P. ovale and P. malariae [23, 24] (Table 1). 
he P92 orthologue from P. knowlesi and 2 paralogues 
from both the MSP3 and MSP7 multigene family from 
P. ovale and P. malariae were also selected since ortho-
logues of these proteins are highly immunoreactive in P. 
falciparum (Table 1). Protein expression plasmids encod-
ing the entire ectodomains for the selected genes were 
made by gene synthesis, and proteins were expressed as 
soluble recombinant proteins by transfecting HEK293 
cells. As expected, protein expression levels varied con-
siderably, and most were expressed at usable levels at the 
expected size (Fig. 1a, Table 1). Exceptions included the 
P38 orthologue from all 3 species, P12 from P. malariae 
and P. ovale, and PmCyRPA, which were all repeatedly 
expressed at low levels in independent transfections. 
PoMSP3.5, PoMSP7.8 and PkP41 showed evidence of 
some proteolytic processing (Fig. 1a). In summary, ortho-
logues of proteins in the genomes of P. knowlesi, P. ovale 
and P. malariae that are highly immunoreactive to sera 
from patients with P. falciparum and P. vivax infections 
were identiied and expressed as soluble recombinant 
proteins for serological screening. 
A smaller subset within the expanded panel of recom-
binant proteins which were immunoreactive needed to 
be identiied as suitable serological markers of infection. 
To determine which of the P. ovale and P. malariae pro-
teins were immunoreactive, the responses to IgG, IgM 
and IgA immunoglobulins were tested using sera pooled 
from over 800 adults living in Malawi [19] where there 
is active transmission for both species [35]. For P. malar-
iae, P41, MSP5, and MSP10 were selected as they were 
the most immunoreactive and expressed at acceptable 
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Table 1 Details of the Plasmodium spp. proteins expressed in this study
Sp. Oicial 
nomenclature
Synonym/s Accession number Region 
expressed
Length 
(aa)
Exp. 
level
PlasmoDB, previous ID Addgene 
ID
P. falciparum MSP1* MSA1, Pf190, 
Pf195
PF3D7_0930300 V20-S1701 1682 Low Merozoite surface 
protein 1
47709
AMA1* Pf83, RMA1, 
PfAMA1
PF3D7_1133400 Q25-T541 517 High Apical membrane anti-
gen 1, PF11_0344
47741
P92* Pf92 PF3D7_1364100 A26-S770 745 Low 6-cysteine protein, 
PF13_0338
47728
MSP4 PF3D7_0207000 Y29-S253 225 Low Merozoite surface pro-
tein 4, PFB0310C
47717
MSP5 PF3D7_0206900.1 N22-S251 230 Low Merozoite surface pro-
tein 5, PFB0305C
47718
P12* Pf12, Pfs12 PF3D7_0612700 H26-S323 298 High 6-cysteine protein, 
MAL6P1, PFF0615C
47725
GAMA PSOP9 PF3D7_0828800 L22-P710 689 Med GPI-anchored microne-
mal antigen
47747
MSP10* PF3D7_0620400 H27-S503 477 Med Merozoite surface pro-
tein 10, MAL6P1.221, 
PFF0995C
47719
P38 Pf38, Pfs38 PF3D7_0508000 Q22-S328 307 High 6-cysteine protein, 
PFE0395C
47727
MSP3.1* MSP3, SPAM PF3D7_1035400 K26-H354 328 Med Merozoite surface pro-
tein 3, PF10_0345
47731
P41 Pf41, Pfs41 PF3D7_0404900 K21-S378 358 High 6-cysteine protein, 
PFD0240C
47739
MSP7 PF3D7_1335100 T28-M351 324 Med Merozoite surface pro-
tein 7, PF13_0197
47735
HPzz* PFA0210c PF3D7_0104200 Y24-D466 443 Low StAR-related lipid trans-
fer protein, MAL1P1.33
50821
P. vivax MSP4 PVX_003775 A26-S227 202 Low Merozoite surface 
protein 4, putative, 
PV003775
68510
MSP5* PVX_003770 R22-S367 346 Med Merozoite surface pro-
tein 5, PV003770
68511
P12* PVX_113775 F24-A339 316 Med 6-cysteine protein, 
PV113775
68516
GAMA PVX_088910 L21-S749 729 Med GPI-anchored microne-
mal antigen, putative, 
PV088910
68522
CyRPA PVX_090240 T23-D366 344 Med Cysteine-rich protec-
tive antigen, putative, 
PV090240
68525
HPzz* PVX_081550 R23-F495 473 Low StAR-related lipid trans-
fer protein, putative, 
PV081550
68532
P38* PVX_097960 K29-G334 306 Med 6-cysteine protein, 
PV097960
68518
MSP7.1* PVX_082700 E22-Y420 399 Med Merozoite surface 
protein 7 (MSP7), 
PV082700
68512
MSP3γ MSP3.1 PVX_097670 N21-K845 825 Med Merozoite surface pro-
tein 3, PV097670
68506
P41* PVX_000995 E22-E384 363 Med 6-cysteine protein, 
PV000995
68519
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Table 1 (continued)
Sp. Oicial 
nomenclature
Synonym/s Accession number Region 
expressed
Length 
(aa)
Exp. 
level
PlasmoDB, previous ID Addgene 
ID
P. malariae CyRPA PmUG01_05040800 E20-D358 339 Low Cysteine-rich protective 
antigen, putative
126817
GAMA PmUG01_05017200 L22-S764 743 High GPI-anchored microne-
mal antigen
126818
MSP10* PmUG01_11043200 N27-S389 363 Low Merozoite surface pro-
tein 10, putative
126819
MSP4 PmUG01_04025600 Y29-S206 178 Low Merozoite surface 
protein 4, putative
126820
MSP5* PmUG01_04025700 K22-L291 270 High Merozoite surface 
protein 5
126821
P12 P12p PmUG01_11050400 Y19-S333 315 Low 6-cysteine protein 126822
P38 PmUG01_06016900 M1-A310 310 Low 6-cysteine protein, 
putative
126823
P41* PmUG01_03015000 Q23-D374 352 Med 6-cysteine protein, 
putative
126824
MSP3.10 PmUG01_06022000 K24-I525 522 High Merozoite surface 
protein 3, putative
126825
MSP3.5 PmUG01_06022600 N21-S562 542 High Merozoite surface 
protein 3, putative
126826
MSP7.1 PmUG01_12029500 R25-I442 418 High MSP7-like protein, 
putative
126827
MSP7.4 PmUG01_12029900 K22-V394 373 High MSP7-like protein, 
putative
126828
P. ovale CyRPA POVCU1_054880 S20-D359 340 Med Cysteine-rich protec-
tive antigen, putative, 
SBS99762.1
126829
GAMA PocGH01_05012100 L22-S755 734 High GPI-anchored microne-
mal antigen, putative
126830
MSP10* PocGH01_11036900 Y27-S430 404 High Merozoite surface pro-
tein 10, putative
126831
MSP4 PocGH01_04023000 N26-S209 184 High Merozoite surface 
protein 4, putative
126832
MSP5 PocGH01_04023100 F20-S311 292 High Merozoite surface 
protein 5, putative
126833
P12 P12p PocGH01_11044100 E23-S301 279 Low 6-cysteine protein 126834
P38 PocGH01_10033500 K25-S332 308 Low 6-cysteine protein, 
putative
126835
P41* PocGH01_03012400 E16-E375 360 Med 6-cysteine protein, 
putative
126836
MSP3.5* PocGH01_10038700 K24-P480 457 Med Merozoite surface 
protein 3, putative
126837
MSP3.6 PocGH01_10038800 K24-S732 709 Low Merozoite surface 
protein 3, putative
126838
MSP7.12 PocGH01_12028800 K23-T441 419 Med MSP7-like protein, 
putative
126839
MSP7.8 PocGH01_12028400 K23-T379 357 Med MSP7-like protein, 
putative
126840
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levels (Fig. 1b); MSP4 was not selected because although 
immunoreactive, was repeatedly expressed poorly. Using 
the same criteria, the P. ovale proteins P41, MSP3.5 and 
MSP10 were selected (Fig.  1b). To identify the most 
suitable antigens for P. knowlesi, the immunoreactiv-
ity to the panel of proteins was tested using sera derived 
from 10 Malaysian patients with PCR-conirmed single 
P. knowlesi infections, and P12, P38 and MSP10 were 
chosen (Fig.  1c). From these experiments, a panel of 22 
proteins were selected that contained 7 proteins from P. 
falciparum, 6 from P. vivax, and 3 from each of P. malar-
iae, P. ovale and P. knowlesi (Table 1).
Using this panel of 22 immunoreactive proteins, the 
antibody responses to a speciic antigen from a particu-
lar Plasmodium species were examined to determine 
whether there was any detectable cross-reactivity with 
antigens from other species. Ideally, this would make 
use of sera from human patients which have diag-
nosed mono-infections for each Plasmodium species. 
To increase the chances that patients had been exposed 
to a single species, serum samples were obtained from 
patients of European origin who had contracted malaria 
by visiting malaria endemic regions and in which the 
infecting Plasmodium species had been conirmed by 
PCR. For the more common parasites, a reasonable num-
ber of samples were obtained: P. falciparum (n = 26), P. 
vivax (n = 17), but access to serum samples of travellers’ 
malaria with diagnosed infections for the rarer parasites 
was limited: P. ovale (n = 7), P. malariae (n = 3). For P. 
knowlesi, responses in the 10 Malaysian patients with 
PCR-conirmed single P. knowlesi infections were used. 
hese patient sera were screened against the panel of all 
22 antigens from ive Plasmodium species. Two patients 
exhibited a broad reactivity to antigens from two spe-
cies: a Swedish traveller diagnosed with P. vivax but 
whose serum exhibited broad reactivity across antigens 
from three Plasmodium species (P. vivax, P. falciparum, 
P. knowlesi) and one of the Malaysian patients diagnosed 
with P. knowlesi but whose serum reacted strongly with 
four out of six P. vivax antigens; this patient was subse-
quently identiied as a migrant worker from Indonesia 
where P. vivax is endemic. Because it is likely that these 
patients had prior exposure to another Plasmodium spe-
cies other than their diagnosed infection, these patients 
were removed from this analysis. he pairwise correla-
tion of the responses to each of the antigens in the panel 
was examined in the remaining patients (Fig.  2a). For 
P. falciparum and P. vivax, where more samples were 
Table 1 (continued)
Sp. Oicial 
nomenclature
Synonym/s Accession number Region 
expressed
Length 
(aa)
Exp. 
level
PlasmoDB, previous ID Addgene 
ID
P. knowlesi CyRPA PKNH_0515800 N23-E366 344 Med Cysteine-rich protec-
tive antigen, putative, 
PKH_052740
126841
GAMA PSOP9 PKNH_1322900 L21-S700 680 Med GPI-anchored microne-
mal antigen, putative, 
PKH_050210
126842
MSP10* PKNH_1129800 N27-S417 391 High Merozoite surface 
protein 10, putative, 
PKH_112880
126940
MSP4 PKNH_0414100 D26-S182 157 Med Merozoite surface 
protein 4, putative, 
PKH_041300
126843
MSP5 PKNH_0414200 H22-S354 333 Med Merozoite surface pro-
tein 5, PKH_041310
126844
P12* PKNH_1137300 F24-S323 300 Med 6-cysteine protein, 
PKH_113620
126845
P38* PKNH_1025600 K3-S367 365 Low 6-cysteine protein, 
PKH_102490
126846
P41 PKNH_0303000 E22-E393 372 High 6-cysteine protein, 
PKH_030970
126847
P92 PKNH_1107200 D24-P857 834 Med 6-cysteine protein, 
PKH_110660
126848
Protein expression plasmids encoding the named genes from the ive Plasmodium species that infect humans are detailed. ‘Region expressed’ refers to the 
ectodomain regions between the predicted signal sequence peptide and the transmembrane or GPI anchor sequence (if present). Expression levels are given as a 
guide only given the signiicant batch‑to‑batch variability observed using this approach and grouped into ‘high’ (between 5 and 50 μg/mL), ‘medium’ (0.5–5 μg/mL) 
and ‘low’ (0.005–0.5 μg/mL). Those proteins selected for further serological analysis are marked with an asterisk
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available, the antibody responses to most antigens within 
that species were positively correlated, as expected 
(Fig. 2a). here were two antigens that showed signiicant 
cross-reactivity between their orthologues: the HPzz 
proteins from P. falciparum and P. vivax, and MSP5 from 
P. vivax and P. malariae. Furthermore, responses to P. 
malariae P41 correlated with P. ovale MSP3.5. his sug-
gested that responses to these proteins may not be suit-
able to diagnose exposure for these species, and so were 
omitted from further analyses. here was no evidence 
that sequence identity between orthologous proteins 
correlated with cross reactivity. For example, the amino 
acid sequence identity between P. falciparum and P. vivax 
HPzz proteins was only 39%, and yet responses showed 
strong evidence of cross-reactivity (Fig. 2b). By contrast, 
the sequence identity between P. knowlesi and P. vivax 
P12 was much higher (72%), and yet patient responses 
showed little evidence of cross-reaction (Fig.  2c). While 
this analysis must come with the caveat that the number 
of serum samples from travellers with malaria is limited, 
especially for the rarer parasites, P. ovale and P. malariae, 
antigens that appeared potentially cross-reactive between 
species were excluded, and this apparent cross-reactiv-
ity did not correlate with sequence identity between the 
orthologous proteins.
Fig. 1 Immunoreactivity of recombinant Plasmodium antigens in sera from adults living in endemic regions. a Expression plasmids encoding the 
entire ectodomains of the proteins from the named species were expressed as enzymatically monobiotinylated soluble recombinant proteins in 
HEK293 cells. Spent tissue culture supernatant was normalized and resolved by SDS-PAGE under reducing conditions, blotted and detected by 
Western blotting using streptavidin-HRP. All proteins contain a C-terminal rat Cd4d3+ 4 and enzymatically biotinylatable tag. The named proteins 
from each species were enzymatically monobiotinylated during expression and captured on streptavidin-coated plates. Pooled sera from Malawian 
adults was used to probe the P. malariae and P. ovale proteins (b), and sera from 10 Malaysian individuals with PCR-confirmed single P. knowlesi 
infections were used for the P. knowlesi (c). Immunoreactivity was quantified by ELISA using an anti-human alkaline-phosphatase conjugated 
secondary antibody that hydrolyzed a substrate forming a product with maximal absorbance at 405 nm; responses were normalized to a control 
protein
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To determine whether the panel of proteins could be 
used in serological assays to establish exposure to difer-
ent human-infective Plasmodium species, a larger panel 
of serum samples from individuals with diagnosed infec-
tions that corresponded to both ongoing acute cases of 
imported malaria (n = 81), and endemic malaria from 
a cohort of Tanzanian adults (n = 21) were tested. For 
P. knowlesi, sera from the 10 patients diagnosed with P. 
knowlesi infections from Kapit Hospital in Malaysian 
Borneo were used. he antibody responses between 
the diferent sources were investigated by segregating 
the samples into three diferent categories: travellers of 
European origin (n = 53), travellers with an origin in a 
malaria-endemic area (n = 28), and individuals resid-
ing in an endemic area (n = 31). he responses to each 
antigen corresponding to the species diagnosis was plot-
ted within each category, and while diferences between 
the diferent patient groupings were observed on a per 
antigen basis (Additional ile 2: Fig. S1a), when averaged 
across the panel, no systematic diferences were observed 
(Additional ile  2: Fig.  S1b). he converse analysis was 
performed whereby the responses to the antigens corre-
sponding to the species other than that in the diagnosis 
were plotted, and again segregated according to the dif-
ferent categories. As expected, there was little response 
across the antigen panel, although it was clear that the 
Tanzanian endemic samples showed evidence of expo-
sure to other species other than the one for which they 
had a diagnosed ongoing infection, especially for P. fal-
ciparum, but also P. ovale (Additional ile  2: Fig.  S1c). 
Immunoreactivity to both HPzz orthologues from both 
P. falciparum and P. vivax and PfMSP1 were observed 
which suggested antigen cross-reactivity, as had been 
already established for HPzz (Fig.  2), or, in the case of 
PfMSP1, there was a higher background signal, including 
from the uninfected controls (Additional ile 2: Fig. S1c).
A logistic-regression classiier was trained to combine 
the immunoreactivities to the antigens from each species 
into a prediction of prior exposure. Sera from both trav-
ellers and individuals living in endemic regions for each 
Fig. 2 Intra-species correlations and cross-species reactivities to serological responses to recombinant Plasmodium spp. antigens. The 
immunoreactivities of the named antigens from each Plasmodium species to diagnosed patient sera were quantified by ELISA and their 
pairwise correlation determined (a). For P. falciparum, P. vivax, P. ovale and P. malariae infections, sera were obtained from Swedish travellers to 
malaria-endemic regions increasing the chances of a mono-infection; P. knowlesi infections were from Malaysian patients. Spearman correlations 
for each antigen pair show some expected clusters of correlations within a species, especially for P. falciparum and P. vivax where more samples 
were available, and potential cross-reactivity between antigens across species were identified. b Serological responses to P. falciparum and P. vivax 
HPzz orthologues are likely to be cross-reactive despite low sequence identity between orthologues. The immunoreactivity to the P. falciparum and 
P. vivax HPzz antigens are plotted for each patient with their diagnosis indicated. c Responses to P. knowlesi and P. vivax P12 orthologues show no 
evidence of cross-reactivity despite high primary protein sequence identity between orthologues. p values from a t-distribution significance test are 
indicated by asterisks. *p < 0.05; **p < 0.01; ***p < 0.001
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species were used together with unexposed control sam-
ples and iteratively and randomly split 50:50 into training 
and testing sets, with approximately equal representation 
of diagnoses for each species. For each Plasmodium spe-
cies, a separate model was trained to assign a binary out-
come indicating if a patient was infected by that species 
or not. A score near zero indicates that the model assigns 
a low probability of the patient being infected with the 
given Plasmodium species, while scores near one indicate 
likely infections. Because patients from endemic regions 
are very likely to have had prior exposure to species other 
than the one they were actively diagnosed with, the posi-
tive training set was deined as patients only with a con-
irmed species diagnosis by microscopy or PCR.
he performance of each diagnostic model was evalu-
ated, and the random sampling procedure into train-
ing and testing sets was iteratively repeated. To quantify 
the models’ performance, the averaged receiver operat-
ing characteristic (ROC) curves for predicting exposure 
to each species (Fig.  3a) was irst calculated. Moderate 
predictive power (area under the curve (AUC) ≥ 0.7) 
was achieved for all species, and especially for P. vivax, 
Fig. 3 Classification of exposure to five human-infective Plasmodium species using a panel of recombinant Plasmodium proteins. a Receiver 
operating characteristic (ROC) curves of the performance of logistic regression models using all non-cross-reactive antigens for each species. 
Immunoreactivity data were randomly halved into training and testing sets, to fit the model and calculate ROC curves respectively; this process was 
repeated ten times to estimate a 95% confidence interval (grey shading). The threshold giving the maximum Youden’s index performance is marked 
with a dot. b Diagnostic scores from each species’ classifier for each patient and control sample. The classifications of 100 models from randomly 
split training and testing data were averaged. Brighter yellow indicates higher confidence in a positive diagnosis, according to the scale indicated. 
Diagnosis type is indicated as P: PCR; M: microscopy
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P. falciparum and P. knowlesi where exposure could be 
predicted with good accuracy (AUC ≥ 0.8). he relatively 
small number of available diagnosed samples for the rarer 
parasites P. ovale (n = 18) and P. malariae (n = 17), lim-
ited the performance of their classiiers, as well as in the 
case of P. malariae, the reliance on just a single antigen 
(PmMSP10) after removing those that showed evidence 
of cross-reactivity.
Diagnostic models were used to determine a likelihood 
of prior exposure of the patients to each of the difer-
ent Plasmodium species (Fig. 3b). In general, the models 
returned a positive prediction for the parasite species 
that agreed with the diagnosis, and the sera from unex-
posed controls being negative. he classiiers performed 
less well on those patients with co-infections and those 
diagnosed by PCR rather than microscopy (Fig.  3b). As 
expected, several individuals showed strong evidence of 
prior exposure to a diferent Plasmodium parasite spe-
cies other than the one for which they were positively 
diagnosed. For example, some individuals positively diag-
nosed with P. ovale infections, also showed evidence of 
prior exposure to P. falciparum and P. vivax.
Following the encouraging performance of the anti-
gen panel in diagnosing infections by P. knowlesi, a larger 
number of serum samples comprising 50 P. knowlesi 
malaria patients and 66 uninfected controls from the 
same region in Malaysia were evaluated. Using the logis-
tic regression model to combine the responses against 
all three antigens (PkMSP10, PkP12, PkP38), P. knowlesi 
infections could be identiied with high conidence 
(AUC > 91%) (Fig.  4a). If a threshold is set to a model 
score of above 0.5, then 82% of P. knowlesi-infected 
patients are correctly diagnosed at a false-positive rate of 
3% (Fig. 4b).
Fig. 4 Accurate serological diagnosis of Plasmodium knowlesi infections using a small panel of recombinant antigens. a ROC curve for a 
logistic regression model combining signal from three P. knowlesi antigens. The shaded 95% confidence interval is estimated from ten random 
sub-samplings of the data into model training and testing sets. The threshold giving the maximum Youden’s index performance is marked with a 
dot. b Average model confidence in P. knowlesi exposure for each patient (colour-coded along the x-axis: grey: uninfected controls, burgundy: P. 
knowlesi-infected diagnosed patient) after 100 rounds of sub-sampling into testing sets
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Discussion
Malaria continues to be a signiicant global health prob-
lem although cases have dropped in recent years due to 
the deployment of efective intervention measures [1]. 
Spurred on by these successes, the malaria control poli-
cies of governments and international agencies are mov-
ing towards the goal of eradication, which will require 
more sensitive detection and tracking of the diferent 
species in endemic regions. he application of serologi-
cal screening may have an increasingly important role as 
transmission declines because the longevity of antibody 
responses should provide a historical record of expo-
sure rather than being limited to the detection of cur-
rent infections [36]. In areas of declining transmission, 
where there are increasing incidences of sub-microscopic 
infection, models using data from serological surveil-
lance have been shown to provide precise estimates of 
parasite transmission [10]. Because of the asexual ampli-
ication of malaria parasites in the blood, those antigens 
expressed during these blood stages are likely to be good 
choices for diagnostic antigens because they are known 
to be particularly immunodominant. Several serological 
assays have been developed to detect exposure to Plas-
modium parasites although few have attempted to dis-
tinguish infections by the diferent species [37]. his has 
mainly been due to the lack of a genome sequence from 
the two parasites, P. ovale and P. malariae, making the 
cloning and expression of many candidate proteins from 
these species di cult. Recent sequencing of P. ovale and 
P. malariae [23, 24] has now permitted the expression 
of several candidate proteins from these parasites. Here, 
a panel of antigens was compiled that are likely to be 
expressed by the blood stages using the recent availability 
of the genome sequences of all ive main species of Plas-
modium parasites that infect humans, together with the 
approach of expressing extracellular parasite proteins in 
a functionally active form using a mammalian expression 
system. After removing those proteins which showed 
evidence of cross-reactive responses, it was found that 
immunoreactivity to the antigens from P. ovale, (MSP10, 
P41), P. malariae (MSP10) and P. knowlesi (MSP10, P12, 
P38), together with logistic regression modelling had 
moderate power to predict prior exposure to these spe-
cies, and performed especially well for P. knowlesi.
Expressing Plasmodium proteins is known to be tech-
nically challenging, possibly due to the unusual codon 
bias or highly repetitive amino acid sequences often 
found in Plasmodium proteins [15, 38]. Most studies 
expressing recombinant antigens for serological assays 
use prokaryotic expression systems (especially Escher-
ichia coli) or cell-free systems, such as wheat germ 
extracts [39–41]. While these expression systems have 
the advantages of being cost efective, high yielding and 
widely available, they may not be suitable for express-
ing extracellular proteins because they usually require 
a reducing environment which would interfere with the 
formation of structurally critical disulide bonds [16, 
42]. While protein refolding procedures can be used, 
they are usually complex, time consuming, and have 
uncertain outcomes which are often hard to deter-
mine if they have been successful [43]. When used for 
serological screening, proteins that do not adopt the 
native conformation are unlikely to be useful in detect-
ing antibodies that recognise conformational epitopes, 
potentially reducing sensitivity. By using a mammalian 
expression system to produce Plasmodium proteins, it 
was previously shown that these recombinant proteins 
can retain conformational epitopes, and shown that for 
the majority of antigens, a large fraction of the immu-
noreactivity to sera from Plasmodium-exposed patients 
is heat labile, demonstrating the beneit of using pro-
teins that retain native folding for serological assays 
[16]. Plasmodium blood-stage proteins expressed using 
this approach have been useful in sero-epidemiological 
studies for P. falciparum [12, 44] and P. vivax [8]. One 
likely consequence of using conformational epitopes 
in serological assays, which are aimed at distinguish-
ing between species, is that the percentage sequence 
identity between orthologous proteins is unlikely to be 
a reliable indicator of cross-reactivity. In the current 
study, a likely cross-reactivity was observed between 
the P. falciparum and P. vivax orthologues of the HPzz 
protein between patients diagnosed with these para-
sites, despite there being only ~ 40% amino acid shared 
sequence identity. By contrast, very little cross-reac-
tivity was observed in patient serological responses 
between the P. vivax and P. knowlesi P12 orthologues 
which are relatively well conserved, sharing > 70% 
amino acid sequence identity. One likely possibil-
ity is that the informative epitopes for these proteins 
are mainly composed of the precise arrangement of 
solvent-exposed amino acids, making overall linear 
sequence identity less important, whereas repeats 
of just a few amino acids, for example the repetitive 
“NANP” motifs in the circumsporozoite protein can be 
highly immunogenic [45].
A panel of three recombinant antigens (PkMSP10, 
PkP12, PkP38), was found to accurately detect exposure 
to P. knowlesi using a serological assay. his compares 
well with a recent study where the authors also selected 
candidates that were orthologous to known immuno-
reactive proteins in P. falciparum, and selected four 
antigens that were associated with P. knowlesi exposure 
[46]. Together, these studies will contribute towards 
the further development of accurate serological assays 
for this parasite which is becoming an increasing 
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public health concern in Southeast Asia, particularly in 
Malaysia where it is now replacing P. falciparum and P. 
vivax as the major cause of malaria [47, 48].
he use of plasma from native Europeans who had 
contracted travellers’ malaria and had been diagnosed 
accurately increased the chances that they had only 
been exposed to a single species which was useful for 
establishing which responses to diferent antigens 
might be cross reactive. However, accessing large num-
bers of these samples was diicult, especially for the 
rarer parasites, P. malariae and P. ovale, and therefore 
it is not certain that these patients had been previously 
exposed to other species of Plasmodium. Together with 
other assays that have been described for serological 
diagnosis of Plasmodium infections [37, 46, 49], this 
panel of proteins will contribute to an assay that will be 
a useful tool for establishing prior exposure to difer-
ent species of Plasmodium parasites. Surveying more 
patient samples in longitudinal cohorts in a variety of 
transmission settings will be necessary to establish 
whether the responses to the proteins described here 
are diferent in patients living in diferent endemic 
regions, and vary according to the age and exposure of 
the patient.
Conclusions
he recent availability of genome sequences for Plasmo-
dium parasites was used to create a panel of recombinant 
proteins corresponding to immunoreactive blood stage 
proteins from ive human-infective Plasmodium species. 
his panel of proteins will provide a basis for develop-
ing serological assays to determine exposure to the dif-
ferent species of parasite for serological surveillance and 
diagnostics.
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